» Articles » PMID: 33392092

Long Non-Coding RNAs: The Regulatory Mechanisms, Research Strategies, and Future Directions in Cancers

Overview
Journal Front Oncol
Specialty Oncology
Date 2021 Jan 4
PMID 33392092
Citations 145
Authors
Affiliations
Soon will be listed here.
Abstract

The development and application of whole genome sequencing technology has greatly broadened our horizons on the capabilities of long non-coding RNAs (lncRNAs). LncRNAs are more than 200 nucleotides in length and lack protein-coding potential. Increasing evidence indicates that lncRNAs exert an irreplaceable role in tumor initiation, progression, as well as metastasis, and are novel molecular biomarkers for diagnosis and prognosis of cancer patients. Furthermore, lncRNAs and the pathways they influence might represent promising therapeutic targets for a number of tumors. Here, we discuss the recent advances in understanding of the specific regulatory mechanisms of lncRNAs. We focused on the signal, decoy, guide, and scaffold functions of lncRNAs at the epigenetic, transcription, and post-transcription levels in cancer cells. Additionally, we summarize the research strategies used to investigate the roles of lncRNAs in tumors, including lncRNAs screening, lncRNAs characteristic analyses, functional studies, and molecular mechanisms of lncRNAs. This review will provide a short but comprehensive description of the lncRNA functions in tumor development and progression, thus accelerating the clinical implementation of lncRNAs as tumor biomarkers and therapeutic targets.

Citing Articles

Long Non-Coding RNAs in Ovarian Cancer: Mechanistic Insights and Clinical Applications.

Basu S, Nadhan R, Dhanasekaran D Cancers (Basel). 2025; 17(3).

PMID: 39941838 PMC: 11815776. DOI: 10.3390/cancers17030472.


Investigating the role of exosomal long non-coding RNAs in drug resistance within female reproductive system cancers.

Shirani N, Abdi N, Chehelgerdi M, Yaghoobi H, Chehelgerdi M Front Cell Dev Biol. 2025; 13:1485422.

PMID: 39925739 PMC: 11802832. DOI: 10.3389/fcell.2025.1485422.


RNA Structure: Past, Future, and Gene Therapy Applications.

Haseltine W, Hazel K, Patarca R Int J Mol Sci. 2025; 26(1.

PMID: 39795966 PMC: 11719923. DOI: 10.3390/ijms26010110.


Dysregulated LINC01133 expression in laryngeal carcinoma: Prognostic implications and predicted ceRNA interactome.

Razipour M, Jamali Z, Sohrabpour S, Heidari F, Lotfi M, Ghadami E Mol Biol Res Commun. 2025; 14(1):93-107.

PMID: 39744510 PMC: 11624609. DOI: 10.22099/mbrc.2024.50390.1996.


PCAT19: the role in cancer pathogenesis and beyond.

Hu H, Luo H, Deng Z Front Cell Dev Biol. 2025; 12:1435717.

PMID: 39744012 PMC: 11688190. DOI: 10.3389/fcell.2024.1435717.


References
1.
Lam M, Li W, Rosenfeld M, Glass C . Enhancer RNAs and regulated transcriptional programs. Trends Biochem Sci. 2014; 39(4):170-82. PMC: 4266492. DOI: 10.1016/j.tibs.2014.02.007. View

2.
Gilligan K, Dwyer R . Engineering Exosomes for Cancer Therapy. Int J Mol Sci. 2017; 18(6). PMC: 5485946. DOI: 10.3390/ijms18061122. View

3.
Wang M, Zhou L, Yu F, Zhang Y, Li P, Wang K . The functional roles of exosomal long non-coding RNAs in cancer. Cell Mol Life Sci. 2019; 76(11):2059-2076. PMC: 11105177. DOI: 10.1007/s00018-019-03018-3. View

4.
Weakley S, Wang H, Yao Q, Chen C . Expression and function of a large non-coding RNA gene XIST in human cancer. World J Surg. 2011; 35(8):1751-6. PMC: 3275083. DOI: 10.1007/s00268-010-0951-0. View

5.
Ratan Z, Zaman S, Mehta V, Haidere M, Runa N, Akter N . Application of Fluorescence In Situ Hybridization (FISH) Technique for the Detection of Genetic Aberration in Medical Science. Cureus. 2017; 9(6):e1325. PMC: 5501716. DOI: 10.7759/cureus.1325. View